Tools
Stock profile

ABBOTT LABORATORIES (ABT)

ABT · Latest close $104.48 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$104.48
As of Nov 18, 2026
Tracked funds holding
11 of 149
2026 Q2 13F filings
Opened / added
2 / 2
vs previous quarter
Trimmed / exited
5
vs previous quarter

ABBOTT LABORATORIES (ABT) is held by 11 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 5 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $46.6M sold). 2 members of Congress reported 4 purchases vs 10 sales. Latest close $104.48 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-46.6M
Congress
4 buys vs 10 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Flossbach von Storch · Southeastern Asset Management · Jensen Investment Management — 11 tracked funds hold ABT. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 4 sales ($46.6M). Insider trading 2 members of Congress reported buying (4 purchases vs 10 sales). Latest buy: Sep 18, 2026. Politician trading

Often held alongside

3M CO (MMM) · GENERAL MILLS INC (GIS) · TARGET CORP (TGT) · CINTAS CORP (CTAS) · NORFOLK SOUTHERN CORP (NSC) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Flossbach von Storch4.08%9,950,828ADDED (+26.6%) Q3 filed Oct 28
Southeastern Asset Management3.98%840,747NEW Q3 filed Nov 16
Jensen Investment Management1.95%885,262TRIMMED (-40.4%) Q3 filed Nov 10
Mairs & Power Funds0.61%729,358ADDED (+1.1%) Q3 filed Nov 16
Saturna Capital0.43%388,939TRIMMED (-0.8%) Q3 filed Nov 16
Matrix Asset Advisors0.35%47,262NEW Q3 filed Oct 13
Sanders Capital0.10%1,050,405TRIMMED (-6.3%) Q3 filed Nov 2
Edgewood Management0.06%68,016HELD Q3 filed Nov 12
Gardner Russo & Quinn0.01%11,510HELD Q3 filed Nov 12
Dodge & Cox Funds<0.01%17,324HELD Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +13.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

140.2280.252024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

182016Q3: 16 funds2016Q4: 16 funds2018Q3: 16 funds2018Q4: 17 funds2019Q3: 16 funds2019Q4: 16 funds2020Q1: 18 funds2020Q3: 17 funds2021Q3: 16 funds2016Q32021Q3

Tracked funds holding this stock, by quarter (2016Q3–2021Q3, 9 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding2,970 of 8,857 filers
Long-only filers among them2,963
Change vs 2026 Q1-91 net · 1,879 entered · 1,970 exited
Shares reported, all filers1,366,328,316
Reported value, all filers$121.9B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$44.3B
Net income · FY2025$6.5B
Total assets · FY2025$86.7B
Shares outstanding1,748,000,000
Market cap (at latest close)$182.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported 2025.

Short interest

Shares short · Oct 15, 202617,386,736
Share of shares outstanding0.99%
Days to cover1.78

Shares short at recent settlements — Jul 31, 2026: 22.6M · Aug 14, 2026: 20.4M · Aug 31, 2026: 22.1M · Sep 15, 2026: 19.9M · Sep 30, 2026: 13.6M · Oct 15, 2026: 17.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 300 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 3 insiders ($46.6M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 5, 2026Moreland Mary KEXECUTIVE VICE PRESIDENTSell3,500$116.00$406.0KSEC filing
Sep 2, 2026MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLERSell27$109.54$3.0KSEC filing
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOSell218,535$115.57$25.3MSEC filing
Aug 25, 2026Ford Robert BCHAIRMAN AND CEOSell180,297$116.19$20.9MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 2, 2026John A. McCoy, Jr.Officer27$3.0KSep 2, 2026SEC filing
Aug 25, 2026Robert B. FordOfficer, Director398,832$46.2MAug 25, 2026SEC filing
Aug 11, 2026Louis H. MorroneOfficer5,850$642.5KAug 11, 2026SEC filing
May 15, 2026Robert J. AlpernRetired Director7,587$646.8KMay 15, 2026SEC filing
Apr 27, 2026Robert J. AlpernRetired Director29,211$2.7MApr 27, 2026SEC filing
Mar 2, 2026Elizabeth C. CushmanOfficer263$30.4KMar 2, 2026SEC filing
Mar 2, 2026Eric ShroffOfficer709$81.9KMar 2, 2026SEC filing
Mar 2, 2026Louis H. MorroneOfficer1,144$132.2KMar 2, 2026SEC filing
Mar 2, 2026Mary K. MorelandOfficer613$70.8KMar 2, 2026SEC filing
Mar 2, 2026John A. McCoy, Jr.Officer585$67.6KMar 2, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 29, 2026Vanguard Capital ManagementSC 13G130,676,7767.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Dec 3, 2025The Vanguard GroupSC 13G/A174,894,07910.1%Nov 28, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

2 members of Congress reported buying (4 purchases vs 10 sales). Bought by Democrats and Republicans. Latest buy: Sep 18, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Sessions, PeteHouseR01Oct 2, 2026$50,001 - $100,000
Cisneros, GilbertHouseD21Sep 18, 2026$1,001 - $15,000
Kean, Thomas H.HouseR01Sep 17, 2026$1,001 - $15,000
McCormick, Richard DeanHouseR21Jul 30, 2026$1,001 - $15,000
Kelly, MikeHouseR01Jul 17, 2026$1,001 - $15,000
Allen, Richard W.HouseR02Jul 14, 2026$15,001 - $50,000
Larsen, RickHouseD01Jul 8, 2026$1,001 - $15,000
Gottheimer, JoshHouseD01May 27, 2026$1,001 - $15,000
Johnson, JulieHouseD01May 12, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

Member who traded this stockSits on
Kean, Thomas H.House Committee on Energy and Commerce
Allen, Richard W.House Committee on Energy and Commerce

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 902 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (579), Taxation/Internal Revenue Code (345), Medicare/Medicaid (338).

Federal contracts: $4.8B in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$2.0B
FY2022$2.1B
FY2023$397.0M
FY2024$106.5M
FY2025$143.2M
FY2026$145.9M

Largest awards collected

Award IDAgencyAmountStart
W58P0522C0008Department of Defense$1.3BJan 12, 2022
SPE2DS21F0101Department of Defense$357.0MSep 2, 2021
SPE2DS21F0129Department of Defense$264.0MSep 24, 2021
75A50223C00001Department of Health and Human Services$257.1MDec 7, 2022
SPE2DE21F0153Department of Defense$152.3MMar 19, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members

Financial Screens

· Graham — Sound finances and a long run of profits

· Dividend Growth — Dividends raised for more than 10 years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Key figures

· Graham — Current ratio: 1.58 · Straight profitable years: 19 · Debt ratio: — · Latest net income: $6.5B

· Dividend Growth — Dividend per share: 2.40 · Dividend yield: 2.3% · Straight dividend years: 7 · 10-yr dividend growth: —

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.12 · Operating cash flow: $9.6B · Net income: $6.5B

· Bought by Members — Members buying: 2 · Buy txns: 4 · Sell txns: 10 · Latest buy: Sep 18, 2026

· Bought by Both Parties — Members buying: 2 · Buy txns: 4 · Sell txns: 10 · Latest buy: Sep 18, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 9 of the last 40 quarterly lists; latest 2021 Q3, ranked #50 of 50.

· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2026 Q2, ranked #44 of 50.

· Politician BEST — appeared in 10 of the last 20 quarterly lists; latest 2026 Q2, ranked #16 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1040.0%-0.9%+0.3%-1.2%
Share count tripled (3x)10.0%-1.8%+8.6%-10.4%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold ABT — ranked by lift, the co-holding pattern described in Methodology: 3M CO (MMM) · GENERAL MILLS INC (GIS) · TARGET CORP (TGT) · CINTAS CORP (CTAS) · NORFOLK SOUTHERN CORP (NSC) · Trane Technologies plc (TT) · AUTOMATIC DATA PROCESSING INC (ADP) · CADENCE DESIGN SYSTEMS INC (CDNS).

Filings audit: every filing lens on ABBOTT LABORATORIES (ABT), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 16, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Oct 21, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 21, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

3M CO (MMM) · Filings audit: every filing lens on ABBOTT LABORATORIES (ABT), scored · Practice timing on ABT

One email a week: the week’s new filings and research. Subscribe free

← ABSI  ·  ABUS →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.